KalVista Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- KalVista Pharmaceuticals's estimated annual revenue is currently $16.4M per year.
- KalVista Pharmaceuticals's estimated revenue per employee is $58,889
- KalVista Pharmaceuticals's total funding is $239.7M.
Employee Data
- KalVista Pharmaceuticals has 279 Employees.
- KalVista Pharmaceuticals grew their employee count by 64% last year.
KalVista Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Commercial Officer | Reveal Email/Phone |
3 | Chief Financial Officer | Reveal Email/Phone |
4 | Chief Operating Officer | Reveal Email/Phone |
5 | Senior Director, Global Safety Officer | Reveal Email/Phone |
6 | Head Insights, Analytics and Sales Operations | Reveal Email/Phone |
7 | Head HCP Marketing / Sebetralstat Launch Lead (Senior Director) | Reveal Email/Phone |
8 | SVP, Regulatory Affairs and QA | Reveal Email/Phone |
9 | VP, Clinical | Reveal Email/Phone |
10 | VP Finance | Reveal Email/Phone |
KalVista Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is KalVista Pharmaceuticals?
KalVista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.
keywords:N/A
$239.7M
Total Funding
279
Number of Employees
$16.4M
Revenue (est)
64%
Employee Growth %
N/A
Valuation
N/A
Accelerator
KalVista Pharmaceuticals News
KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded at Zacks Investment Research. Posted by admin on Apr 21st, 2022. Share on Twitter Share on Facebook Share on...
KalVista Pharmaceuticals (NASDAQ:KALV) versus Aridis Pharmaceuticals (NASDAQ:ARDS) Head-To-Head Analysis. Posted by admin on Apr 16th, 2022.
KalVista Pharmaceuticals (NASDAQ:KALV) Downgraded by Zacks Investment Research to Sell. Posted by admin on Apr 14th, 2022.
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Mar 19, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Nancy Stuart has ...
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Mar 11, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $38.4M | 279 | 45% | N/A |
#2 | $101.4M | 281 | 8% | N/A |
#3 | $15M | 281 | 13% | N/A |
#4 | $54.6M | 282 | 0% | $132.9M |
#5 | $0M | 285 | -5% | $480.6M |